Results 231 to 240 of about 74,951 (264)

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul Parikh
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly  

Endocrine tumours, somatostatin and somatostatin receptors.

Acta gastro-enterologica Belgica, 2005
Somatostatin blocks the release of numerous growth factors and is therefore a potent inhibitor of cell division and/or secretion. It exerts its effects through binding to somatostatin receptors. Five different subtypes of such receptors are identified (SSTR1 to SSTR5), having various tissue expression.
J, Rahier, Y, Guiot, C, Sempoux
openaire   +1 more source

Somatostatin Receptors in Pheochromocytoma

2003
de Herder, W.W., Hofland, Leo
openaire   +3 more sources

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Grace M Choong, Grace D Cullen, Ciara C O'sullivan   +2 more
exaly  

Somatostatin Receptor Imaging

2004
Kwekkeboom, Dik, Jong, Marion, Krenning, Eric   +2 more
openaire   +2 more sources

Somatostatin Receptors

2022
openaire   +1 more source

Somatostatin Receptors

2015
Miguel J. -M. Lewin, Muriel Le Romancer
openaire   +2 more sources

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly